JP2009507014A - S−クロピドグレルの新規レジネート複合体およびその生成法 - Google Patents
S−クロピドグレルの新規レジネート複合体およびその生成法 Download PDFInfo
- Publication number
- JP2009507014A JP2009507014A JP2008528932A JP2008528932A JP2009507014A JP 2009507014 A JP2009507014 A JP 2009507014A JP 2008528932 A JP2008528932 A JP 2008528932A JP 2008528932 A JP2008528932 A JP 2008528932A JP 2009507014 A JP2009507014 A JP 2009507014A
- Authority
- JP
- Japan
- Prior art keywords
- clopidogrel
- complex
- water
- isomer
- sulfonic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F12/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
- C08F12/02—Monomers containing only one unsaturated aliphatic radical
- C08F12/04—Monomers containing only one unsaturated aliphatic radical containing one ring
- C08F12/14—Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing heteroatoms
- C08F12/30—Sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F12/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
- C08F12/34—Monomers containing two or more unsaturated aliphatic radicals
- C08F12/36—Divinylbenzene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/20—Manufacture of shaped structures of ion-exchange resins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Diabetes (AREA)
- Materials Engineering (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【選択図】図1
Description
組成1
組成2
(比較例1)
(比較例2)
(実験例1)
(実験例2)
(実験例3)
表1
Claims (10)
- (+)‐クロピドグレル異性体がスルホン酸基を有する水溶性陽イオン交換樹脂と結合することを特徴とする、(+)‐クロピドグレル異性体のレジネート複合体。
- スルホン酸基を有する前記水溶性陽イオン交換樹脂が前記(+)‐クロピドグレル異性体と重量で1:0.1〜1:10の比率で結合することを特徴とする、請求項1に記載の(+)‐クロピドグレル異性体のレジネート複合体。
- スルホン酸基を有する1種類以上の水溶性陽イオン交換樹脂が、分子量が5,000〜1,000,000の範囲の陽イオン交換樹脂から選択されることを特徴とする、請求項1に記載の(+)‐クロピドグレル異性体のレジネート複合体。
- スルホン酸基を有する1種類以上の水溶性陽イオン交換樹脂が、スチレンスルホン酸ポリマーおよびジビニルベンゼンスチレンスルホン酸共重合体からなる群から選択されることを特徴とする、請求項1に記載の(+)‐クロピドグレル異性体のレジネート複合体。
- スルホン酸基を有する前記水溶性陽イオン交換樹脂が、スチレンスルホン酸ポリマーから選択される1種類以上のポリマーを有することを特徴とする、請求項4に記載の(+)‐クロピドグレル異性体のレジネート複合体。
- 前記(+)‐クロピドグレル異性体レジネート複合体に残存する前記スルホン酸基がアルカリ物質によりマスキングされることを特徴とする、請求項1に記載の(+)‐クロピドグレル異性体のレジネート複合体。
- 1種類以上のアルカリ物質が、アルカリ金属および土類金属、およびアミンから選択されることを特徴とする、請求項6に記載の(+)‐クロピドグレル異性体のレジネート複合体。
- (+)‐クロピドグレル異性体がスルホン酸基を有する水溶性陽イオン交換樹脂と結合することを特徴とする、前記(+)‐クロピドグレル異性体のレジネート複合体を含む固形の薬品成分。
- スルホン酸基を有する水前記水溶性陽イオン交換樹脂が前記(+)‐クロピドグレル異性体と重量で1:0.1〜1:10の比率で結合することを特徴とする、請求項8に記載の固形の薬品成分。
- スルホン酸基を有する前記水溶性陽イオン交換樹脂と水溶状態の前記(+)‐クロピドグレル異性体とが結合することを特徴とする、前記(+)クロピドグレル異性体のレジネート複合体の製造プロセス。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20050087628 | 2005-09-21 | ||
PCT/KR2006/003346 WO2007035028A1 (en) | 2005-09-21 | 2006-08-24 | Novel resinate complex of s-clopidogrel and production method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2009507014A true JP2009507014A (ja) | 2009-02-19 |
Family
ID=37889044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008528932A Pending JP2009507014A (ja) | 2005-09-21 | 2006-08-24 | S−クロピドグレルの新規レジネート複合体およびその生成法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080226579A1 (ja) |
EP (1) | EP1926736A4 (ja) |
JP (1) | JP2009507014A (ja) |
KR (1) | KR100736024B1 (ja) |
CN (1) | CN101253179B (ja) |
AU (1) | AU2006292946B2 (ja) |
CA (1) | CA2618187C (ja) |
WO (1) | WO2007035028A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015045604A1 (ja) * | 2013-09-30 | 2015-04-02 | 富士フイルム株式会社 | 口腔内崩壊錠 |
WO2018203548A1 (ja) * | 2017-05-01 | 2018-11-08 | 日産化学株式会社 | 水溶性が改善されたアニオン性高分子化合物の調製方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090163449A1 (en) * | 2007-12-20 | 2009-06-25 | Eastman Chemical Company | Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives |
EP2377520A1 (de) * | 2010-03-24 | 2011-10-19 | Ratiopharm GmbH | Pharmazeutische Zusammensetzung des Prasugrels |
CN111060625B (zh) * | 2019-12-31 | 2022-04-05 | 北京鑫开元医药科技有限公司 | 2-(噻吩-2-基)乙基对甲苯磺酸酯及其异构体的检测方法 |
KR20230126068A (ko) | 2022-02-22 | 2023-08-29 | 인제대학교 산학협력단 | 양이온교환수지를 사용한 약물의 방출 조절을 위한 조성물 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2990332A (en) * | 1958-04-02 | 1961-06-27 | Wallace & Tiernan Inc | Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith |
US3138525A (en) * | 1961-06-16 | 1964-06-23 | Hoffmann La Roche | Castor wax-amprotropine-resin compositions |
US3608063A (en) * | 1969-08-15 | 1971-09-21 | Gilbert S Banker | Molecular drug entrapment process and compositions |
US3901248A (en) * | 1970-07-22 | 1975-08-26 | Leo Ab | Chewable smoking substitute composition |
US3987163A (en) * | 1973-07-27 | 1976-10-19 | Burton, Parsons And Company, Inc. | Polystyrene sulfonate containing opthalmic solutions |
US4369175A (en) * | 1981-07-27 | 1983-01-18 | Ciba-Geigy Corporation | Process for the manufacture of prolonged action vincamine preparations, the vincamine preparations so obtained, and medicaments containing them |
US4459278A (en) * | 1983-03-07 | 1984-07-10 | Clear Lake Development Group | Composition and method of immobilizing emetics and method of treating human beings with emetics |
US4762709A (en) * | 1983-09-16 | 1988-08-09 | Pennwalt Corporation | Liquid prolonged release pharmaceutical formulations containing ionic constituents |
US4788055A (en) * | 1985-12-09 | 1988-11-29 | Ciba-Geigy Corporation | Resinate sustained release dextromethorphan composition |
FR2623810B2 (fr) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
IL90245A (en) * | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it |
US5219563A (en) * | 1988-05-11 | 1993-06-15 | Glaxo Group Limited | Drug adsorbates |
US4996047A (en) * | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
SE9103110D0 (sv) * | 1991-10-24 | 1991-10-24 | Kabi Pharmacia Ab | New drug formulation |
FR2744918B1 (fr) * | 1996-02-19 | 1998-05-07 | Sanofi Sa | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
US5980882A (en) * | 1997-04-16 | 1999-11-09 | Medeva Pharmaceuticals Manufacturing | Drug-resin complexes stabilized by chelating agents |
FR2779726B1 (fr) * | 1998-06-15 | 2001-05-18 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
FR2792836B3 (fr) * | 1999-04-30 | 2001-07-27 | Sanofi Sa | Composition pharmaceutique sous forme unitaire contenant de l'aspirine et de l'hydrogenosulfate de clopidogrel |
US6514492B1 (en) * | 1999-07-14 | 2003-02-04 | Schering-Plough Veterinary Corporation | Taste masking of oral quinolone liquid preparations using ion exchange resins |
SE9904377D0 (sv) * | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
US6800668B1 (en) * | 2001-01-19 | 2004-10-05 | Intellipharmaceutics Corp. | Syntactic deformable foam compositions and methods for making |
US6767913B2 (en) * | 2001-12-18 | 2004-07-27 | Teva Pharmaceutical Industries Ltd. | Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms |
US6800759B2 (en) * | 2002-08-02 | 2004-10-05 | Teva Pharmaceutical Industries Ltd. | Racemization and enantiomer separation of clopidogrel |
CZ297472B6 (cs) | 2002-08-27 | 2006-12-13 | Zentiva, A.S. | Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I |
ITMI20022228A1 (it) * | 2002-10-21 | 2004-04-22 | Dinamite Dipharma S P A | Sali di clopidogrel con acidi alchil-solforici. |
DE10305984A1 (de) * | 2003-02-13 | 2004-09-02 | Helm Ag | Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen |
US20050059696A1 (en) * | 2003-05-08 | 2005-03-17 | Dr. Reddy's Laboratories Limited | Process for the recovery of S -(+)-methyl- (2-chlorophenyl)- (6,7-dihydro- 4H-thieno [3,2-c] pyrid-5-yl) acetate hydrogen sulfate (clopidogrel bisulfate) from its (R) and mixture of (R) and (S)- isomers |
US8029822B2 (en) * | 2003-05-22 | 2011-10-04 | Osmotica Kereskedelmi és Seolgáltató KFT | Rupturing controlled release device having a preformed passageway |
US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
US20050112198A1 (en) * | 2003-10-27 | 2005-05-26 | Challapalli Prasad V. | Bupropion formulation for sustained delivery |
US20050181050A1 (en) * | 2004-01-28 | 2005-08-18 | Collegium Pharmaceutical, Inc. | Dosage forms using drug-loaded ion exchange resins |
DE102005060690B4 (de) * | 2005-12-15 | 2008-09-25 | Capsulution Nanoscience Ag | Salze von Clopidogrel mit Polyanionen und ihre Verwendung zur Herstellung pharmazeutischer Formulierungen |
-
2006
- 2006-08-24 JP JP2008528932A patent/JP2009507014A/ja active Pending
- 2006-08-24 US US12/065,104 patent/US20080226579A1/en not_active Abandoned
- 2006-08-24 EP EP06783733A patent/EP1926736A4/en not_active Withdrawn
- 2006-08-24 CN CN2006800320268A patent/CN101253179B/zh not_active Expired - Fee Related
- 2006-08-24 AU AU2006292946A patent/AU2006292946B2/en not_active Ceased
- 2006-08-24 CA CA2618187A patent/CA2618187C/en not_active Expired - Fee Related
- 2006-08-24 WO PCT/KR2006/003346 patent/WO2007035028A1/en active Application Filing
- 2006-08-24 KR KR1020060080339A patent/KR100736024B1/ko active IP Right Grant
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015045604A1 (ja) * | 2013-09-30 | 2015-04-02 | 富士フイルム株式会社 | 口腔内崩壊錠 |
JPWO2015045604A1 (ja) * | 2013-09-30 | 2017-03-09 | 富士フイルム株式会社 | 口腔内崩壊錠 |
WO2018203548A1 (ja) * | 2017-05-01 | 2018-11-08 | 日産化学株式会社 | 水溶性が改善されたアニオン性高分子化合物の調製方法 |
JPWO2018203548A1 (ja) * | 2017-05-01 | 2020-03-12 | 日産化学株式会社 | 水溶性が改善されたアニオン性高分子化合物の調製方法 |
JP7124820B2 (ja) | 2017-05-01 | 2022-08-24 | 日産化学株式会社 | 水溶性が改善されたアニオン性高分子化合物の調製方法 |
US11555080B2 (en) | 2017-05-01 | 2023-01-17 | Nissan Chemical Corporation | Method for preparing anionic macromolecular compound exhibiting improved water solubility |
Also Published As
Publication number | Publication date |
---|---|
KR100736024B1 (ko) | 2007-07-06 |
AU2006292946B2 (en) | 2009-12-10 |
CN101253179B (zh) | 2010-12-29 |
US20080226579A1 (en) | 2008-09-18 |
CA2618187A1 (en) | 2007-03-29 |
AU2006292946A1 (en) | 2007-03-29 |
EP1926736A4 (en) | 2010-08-25 |
CA2618187C (en) | 2011-06-21 |
CN101253179A (zh) | 2008-08-27 |
WO2007035028A1 (en) | 2007-03-29 |
EP1926736A1 (en) | 2008-06-04 |
KR20070033252A (ko) | 2007-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5671560B2 (ja) | 固体投与形中のテトラサイクリン金属錯体 | |
TWI522100B (zh) | 含有納布啡(nalbuphine)之藥學組成物及其用途 | |
US11279682B2 (en) | Vortioxetine pyroglutamate | |
WO2008072534A1 (ja) | マンニトール又は乳糖を含有する固形製剤 | |
JP2009507014A (ja) | S−クロピドグレルの新規レジネート複合体およびその生成法 | |
WO2011136751A2 (en) | Water soluble pharmaceutical composition | |
US20050203115A1 (en) | Narcotic-NSAID ion pairs | |
KR102276281B1 (ko) | 의약으로 사용하기 위한 펄린돌 광학이성질체의 약학적으로 허용가능한 염 | |
WO2007049626A1 (ja) | カベルゴリン含有経口固形製剤 | |
KR100523242B1 (ko) | 이부프로펜을 함유하는 정제 조성물 | |
WO1999041233A1 (en) | A watersoluble nimesulide adduct also for injectable use | |
WO2015199115A1 (ja) | 経口投与用医薬組成物 | |
JPS589082B2 (ja) | 小粒剤の製造法 | |
JP2013032289A (ja) | ワックス安定製剤 | |
JPH023609A (ja) | 塩酸ニカルジピンを活性成分とする持効性製剤 | |
OA18808A (en) | Vortioxetine Pyroglutamate. | |
KR20130037802A (ko) | 프라미펙솔을 포함하는 서방성 미립자 및 이를 포함하는 조성물 | |
CN104352461A (zh) | 他达拉非的口服药物制剂 | |
KR20070119885A (ko) | 생체이용율이 개선된 멜록시캄 함유 조성물 및 그의제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110525 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110607 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110902 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110909 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111005 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120117 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120619 |